ArticleThe breast journal2022

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.

Benjamin James Hall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.